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Statement of translational relevance. We report the generation of a large number of patient-derived
xenografts (PDXs) (MDA PCa PDX series) representative of the clinical spectrum of prostate cancer
(PCa). The MDA PCa PDX series is a dynamic resource that captures the molecular landscape of PCas
over time. It provides insight into the biological basis that accounts for heterogeneity and serves as an
invaluable resource for discovery, therapy development, and optimization of personalized therapy
targeting PCa-specific molecular markers. The models developed thus far have led to the identification
of clinically relevant therapy targets and have proven valuable for drug testing.
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ABSTRACT:
Background: Advances in prostate cancer (PCa) lag behind other tumor types partly due to the
paucity of models reflecting key milestones in PCa progression. Objective: To develop clinically
relevant PCa models. Design: Since 1996 we have generated clinically annotated patient-derived
xenografts (PDXs) (the MDA PCa PDX series) linked to specific phenotypes reflecting all aspects of
clinical PCa. Results: We studied two cell line–derived xenografts and the first 80 PDXs derived from
47 human PCa donors. Of these, 47 PDXs derived from 22 donors are working models and can be
expanded either as cell lines (MDA PCa 2a and 2b) or PDXs. The histopathologic, genomic, and
molecular characteristics (AR, ERG, and PTEN loss) maintain fidelity with the human tumor and
correlate with published findings. PDX growth response to mouse castration and targeted therapy
illustrate their clinical utility. Comparative genomic hybridization and sequencing show significant
differences in oncogenic pathways in pairs of PDXs derived from different areas of the same tumor.
We also identified a recurrent focal deletion in an area that includes the SPOPL gene in PDXs derived
from 7 human donors out of 28 studied (25%). SPOPL is a SPOP paralog, and SPOP mutations define
a molecular subclass of PCa. SPOPL deletions are found in 7% of TCGA PCas, which suggests that
our cohort is a reliable platform for targeted drug development. Conclusions: The MDA PCa PDX
series is a dynamic resource that captures the molecular landscape of PCas progressing under novel
treatments and enables optimization of PCa-specific, marker-driven therapy.
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INTRODUCTION
Metastatic prostate cancer (PCa) that progresses after androgen ablation therapy (i.e., castrationresistant PCa [CRPC]) remains incurable. PCa consist of clinical subsets including the typical prostate
adenocarcinoma with a predictable pattern of progression, as well as other subsets with atypical
clinical behavior similar to that of prostatic small cell neuroendocrine carcinoma (aggressive variant
PCa [AVPC]), which accounts for about 40% of lethal PCa (1, 2). PCa is also heterogeneous at the
morphological and molecular level (3). Thus, responses to targeted therapies differ between
subpopulations of PCa patients, and it is essential to have a spectrum of biological models that reflect
the diverse clinical, morphological, and molecular PCa phenotypes to further research and therapy
development.
PCa research has historically suffered from a lack of patient-derived models. Efforts to develop PCa
patient-derived xenografts (PDXs) have been undertaken in several institutions (4). However, few PCa
PDX banks with substantial number of models have been established. Some contain PDXs derived
from autopsy samples (the LuCaP series) with no information on tumor progression after the samples
have been acquired. Others are mainly derived from primary tumors (the Living Tumor Laboratory
[LTL] series and the PC series developed in Erasmus Medical Center, Rotterdam, The Netherlands)
(4). Therefore, despite these efforts, we still lack a collection of clinically annotated PCa PDXs that
reflects the full spectrum of potentially lethal disease, namely therapy-naïve and therapy-resistant PCas
reflecting clinical and morphological variants derived from primary sites as well as metastases, and can
be related to the tumor donor’s progression to therapy, which is monitored by expert genitourinary
(GU) oncologists. We have approached this challenge by establishing PDXs using tissue specimens
taken from patients with potentially lethal PCa undergoing surgical resection or biopsy of primary
tumors and/or metastatic sites demonstrating clinical progression. This is an ongoing program that
provides a diverse repository of well-annotated tissue samples and PDXs that can be linked
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prospectively with specific stages and states of PCa progression and also reflects the clinical and
molecular evolution of therapy resistant PCa.
Here, we report the morphological and molecular characterization of two cell line–derived xenografts
and the first 80 PDXs derived from 47 human PCa donors developed in our program. Of these, 47
PDXs derived from 22 donors are working models and can be expanded either as cell lines (MDA PCa
2a and 2b) or PDXs. The present study constitutes the foundation for the development and use of
PDXs for precision oncology. Furthermore, as this is a dynamic repository, we also established PDXs
from human PCa that are not described in this report because they are currently being characterized
and will be the subject of a follow up publication. These new PDXs include those derived from PCas
progressing on new hormonal agents, enzalutamide and abiraterone. Enquiries about their availability
to the scientific community can be sent to the corresponding author of this publication.
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Materials and Methods
The PCa PDX Program at MD Anderson Cancer Center
To efficiently process all aspects of PDX development, the MDA PCa PDX program operates within a
highly integrated network of physicians, scientists, laboratory staff, and resources within the Tissue
Biospecimen and Pathology Resource at MD Anderson. These individuals include urologists,
oncologists, interventional radiologists, and pathologists, as well as staff who provide regulatory
compliance support for archived biospecimen requests, consent validation, material transfer
agreements, data management, and sample distribution.
PDX development
In our program, PCa tissue samples used for PDX development were derived from therapeutic or
diagnostic procedures, namely, radical prostatectomies, orthopedic and neurosurgical procedures to
palliate complications, and biopsies of metastatic lesions. Written informed consent was obtained from
patients before sample acquisition, and all samples were processed according to a protocol approved
by the Institutional Review Board of the University of Texas MD Anderson Cancer Center. The studies
were conducted in accordance with the Belmont Report and the US Common Rule. On collection, the
specimens were placed in cold (4°C), sterile α-MEM (GIBCO; Invitrogen), and small pieces were then
implanted into subcutaneous pockets of 6- to 8-week-old male CB17 SCID mice (Charles River
Laboratories) (Fig 1A). Tissue adjacent to the implanted samples (mirror image) were formalin-fixed
and paraffin-embedded (FFPE), and tissue sections were used for quality control. Mice were monitored
weekly for tumor growth. Once the initial implanted tumor grew in the mouse (passage 0 [P0]), it was
harvested and sequentially passaged to five mice (Fig 1A). At each mouse-to-mouse passage,
representative samples of each PDX were frozen in a DMSO solution for later implantation and PDX
expansion, FFPE, flash-frozen, and frozen in OCT medium for histopathological and molecular studies
(Fig 1A).
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To achieve a reliable and reproducible method for PDX development, we established a standard
operating procedure (SOP) with an optimized process for tissue samples, including shortening the time
from sample acquisition to implantation in mice and selecting tissue samples with the highest
percentage of viable cells. We do not maintain PDXs in mice unless they are being utilized by
investigators to perform experiments. Historically, once initial growth was observed and the PDX
underwent five or more serial passages in mice, the likelihood that the model would continue to
propagate in mice is high (80%-90%). Also, in our experience most PDXs will regrow after
cryopreservation either in the first or second attempt, provided that the tissue used for cryopreservation
was obtained from a PDX that reached passage 5. Every time we harvested tissue for cryopreservation,
a mirror tissue sample for quality control was obtained. The viability of tissue at the time of
cryopreservation is essential for regrowth. One caveat is that we have not tested the viability of
cryopreserved tissue for more than one year as we have consistently generated new vials at shorter
intervals.
All animal experiments were conducted in accordance with accepted standards of animal care and were
approved by the Institutional Animal Care and Use Committee at The University of Texas MD
Anderson Cancer Center.
PDX growth in intact and castrated mice
All studies were performed using 6- to 8-week-old male CB17 SCID mice. Twenty-three mice were
subcutaneously implanted with MDA PCa 183-A. Nine of these mice were monitored for tumor
growth over time (intact mice). Seven were castrated when tumor volume was equal or higher than 500
mm3 (castrated mice). The remaining 7 mice were monitored for tumor volume before and ten days
after castration (tumor volume before and after castration).
Twenty-one mice were subcutaneously implanted with MDA PCa 180-30. Seven of these mice were
monitored for tumor growth (intact mice), and fourteen were castrated when tumor volume was equal
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or higher than 500 mm3. Values were used for the plots of castrated mice and tumor volume before and
after castration.
PDX growth intrabone in mice treated with vehicle or FGFR inhibitor
Twenty-three male CB17 SCID mice were injected with cells derived from MDA PCa 118b into the
distal ends of the femurs according to published protocols (5). Twelve days after cell injection, ten
mice were treated with vehicle and thirteen with erdafitinib (Janssen Pharmaceuticals) by oral gavage.
Using the same protocol, twenty male CB17 SCID mice were injected with cells derived from MDA
PCa 183-A into the distal ends of their femurs. Twenty-three days after cell injection, ten mice were
treated with vehicle and ten with erdafitinib by oral gavage. After three weeks of treatment of MDA
PCa 118b–bearing mice and five weeks of treatment of MDA PCa 183-A–bearing mice, tumor volume
was measured from serial sagittal MR images in vehicle- and erdafitinib-treated mice as previously
reported (6).
Statistical Methods
For the studies on tumor size response to mice castration, the change of tumor volume over time was
explored using spaghetti plots. Linear mixed models were fit to assess the change of tumor volume
over time in all groups, while taking into account the intra-mouse correlations. All statistical analyses
were performed using SAS and Splus.
Two-sample t tests were used to study tumor volume response to erdafitinib treatment.
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RESULTS
The PCa PDX Program at MD Anderson Cancer Center
In 1996, we initiated efforts to develop patient-derived models of PCa and established two cell lines
(MDA PCa 2a and MDA PCa 2b) (7). Subsequent attempts (n = 25) at establishing in vitro models
were unsuccessful. These attempts include PCa samples obtained at radical prostatectomy and
samples from different metastatic sites (bone, lymph node, skin, and ascites). The methods used
during these attempts have been previously published (8). In the cases derived from primary PCa, we
saw initial cell growth in most cases, but normal prostatic epithelial cell overgrowth was the most
common outcome. In the cases derived from metastases, we frequently obtained short-term cultures,
but the cells eventually stopped growing or underwent cell death. Methods and alternatives used during
these attempts are discussed in a previous publication (8).
From 1996 to April 2010, we processed PCa tissue samples from 163 patients for PDX development,
including samples from different areas of the same tumor in order to understand tumor heterogeneity.
In total, during that period, we established 80 PDXs derived from 47 human PCa donors; of these, 47
PDXs derived from 22 donors are working models and can be expanded either as cell lines or PDXs
(Table 1, Table S1, and Supplementary Results). These PDXs are named: MDA PCa followed by a
number unique to the donor tumor, tumor site, and procedure date. Currently, the success rate for PDX
development is 30% to 40%, irrespective of the site of origin of the tissue. The variability probably
depends on the amount of viable tissue submitted for PDX development. It takes between 3 months
and 3 years (depending on the rate of growth) for a tissue sample implanted in mice to be passed
through 5 mice sequentially. The PDXs developed are derived from primary PCas or areas of direct
extension to adjacent organs (bladder, rectum) and from metastases, and include therapy-naïve and resistant adenocarcinomas, as well as clinical and histopathological subtypes (Fig 1A, Tables 1 and
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S1). For brevity, from now on the term ‘PDXs’ will be inclusive of MDA PCa 2a-T and 2b-T
xenografts (T indicates a cell line–derived xenograft).
As previously mentioned, this is a dynamic repository and, to date, in addition to the PDXs described
in this report, we have also established PDXs from 52 PCa patients, which are currently being
characterized. These PDXs derived from primary sites, bone or soft tissue metastases include those
derived from treatment naïve PCas and PCas progressing on first and second generation androgen
deprivation therapy, chemotherapy and other therapies.
Morphological and immunohistochemical features of human donor tumors and PDXs
Early and late passage PDXs (passage 1-3 and 5-6, respectively) retain the morphology of the human
PCa donor (Table 1). PDXs also have the same immunohistochemical (IHC) profile (androgen receptor
[AR], synaptophysin [SNP], chromogranin A [CGA], or CD56 [NCAM]) as their human PCa donor
and are either adenocarcinomas (Fig 1B) or neuroendocrine carcinomas (NEC), which includes small
cell morphology (Fig 1C). PDXs established from mixed adenocarcinoma and NEC, reflect one or both
morphological components present in the human PCa (Fig 1D and S1, Supplementary Results). NEC
PDXs are all AR-negative and positive for one or more neuroendocrine markers (SNP, CGA, or CD56)
(9) (Fig 1C, Table 1, Supplementary Results). Adenocarcinomas with negative or low expression of
AR and negative expression of SNP and CGA (e.g., MDA PCa 83 and MDA PCa 118b) fit the recently
published definition of double-negative PCas (10).
Of the 47 donor tumors used to establish the PDXs, 32 are adenocarcinomas (68%), and 11 are NEC or
mixed adenocarcinoma and NEC (23%) (Fig 1E and Table 1). This distribution recapitulates the
morphological landscape of potentially lethal human PCa (1, 2). In the other 4 cases (9%), either there
is no material available for review (e.g., serous fluids), there are no malignant cells based on the
pathology report, or they are unusual PCa morphologies (Table 1 and S1, Supplementary Results).
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AR, ERG, and PTEN status in PDXs and a subgroup of 15 PDX–human donor tumor pairs
Previous reports indicate that 50% to 60% of human PCas have recurrent rearrangements involving
ERG, ETV1, ETV4, or ETV5. AR signaling status, a critical determinant of PCa behavior, is a
therapeutic target for PCa, and aberrant ERG expression cooperates with PTEN deletions to promote
PCa progression (11). IHC and fluorescent in situ hybridization (FISH) analyses of these genes
demonstrated that adenocarcinoma PDXs derived from 27 of the 29 human donors available for study
are AR-positive (93%), and ERG expression is positive in 12 of 26 of the AR-positive samples
available for study (46%) (Fig 1F). MDA PCa 2a-T and 2b-T and MDA PCa 177 have ETV1
rearrangement as confirmed by FISH and RNA-ISH (12) (Fig S2). PDXs derived from NECs, which
do not express AR, also do not express ERG in all but one case (Table S2). PDXs derived from 18 of
26 adenocarcinomas (69%) available for evaluation have homo- or heterozygous PTEN deletion (Fig
1F, Table S2, Supplementary Results). PDXs derived from 6 of 7 NECs (86%) have homo- or
heterozygous PTEN deletion (Fig 1F). PTEN status is variable in PDXs derived from mixed
adenocarcinoma and NEC (Table S1). In summary, the morphological distribution and molecular
features of the PDXs established are consistent with the reports on human PCa in the general
population (13).
Finally, to further understand how AR, ERG and PTEN status in PCa PDXs recapitulate human PCa
donors, we studied 15 PDX–human donor pairs and found concordance in most samples. Fig 2 shows
results of the 11 pairs that are not archived, more details are in Supplementary Results.
MDA PCa PDX growth in intact and castrated male mice
Androgen ablation is the standard first-line treatment for metastatic PCa. The response duration is
highly variable and second-generation androgen ablation therapeutics (abiraterone and enzalutamide)
have significant activity in patients with CRPC. Nevertheless, the emergence of resistance remains
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inevitable in most cases. Thus, to develop effective treatment strategies aimed at improving patient
management, there is an urgent need to further understand the mechanisms that account for treatment
response and resistance.
To assess the potential utility of our models in furthering our understanding of the mechanisms
underlying CRPC progression and to develop effective therapies, we studied the effect of surgical
castration of PDX-bearing mice on the growth of the tumors. Testosterone levels in intact male mice
were shown to mimic standard androgen ablation, and in castrated mice mimic abiraterone-treated
patients (14). Castration was performed as previously published (7). For these studies we selected two
models, MDA PCa 183-A, derived from a treatment-naïve PCa, and MDA PCa 180-30, derived from a
PCa that progressed on androgen deprivation and chemotherapy.
Change of tumor volume over time in the intact and castrated groups was assessed by a linear mixed
model, while considering the intra-mouse correlations. We found a statistically significant difference
between the slopes of the tumor volumes in subcutaneous MDA PCa 183-A growing in intact and
castrated mice (P < 0.0001) (Fig 3A). Accordingly, when we analyzed the growth slope of MDA PCa
183-A before and after castration in the same mouse, we found a statistically significant increase in
tumor volume before castration (slope = 26.8, P < 0.0001) and a statistically significant decrease in
tumor volume after castration (slope = -18.0, P < 0.0001). Of interest, in the castrated group, tumors in
three out of seven mice grew fast and reached a volume above what is allowed by our animal facilities
guidelines and had to be killed. The tumor volume in the other four mice either plateaued and/or
showed a subsequent decline (Fig 3A). Although the small number of mice does not have enough
power for a statistically significant conclusion, these results suggest that two different populations of
cells exist in MDA PCa 183-A PDXs, which is in alignment with the fact that the cells were derived
from an untreated human tumor and therefore there was no prior treatment selection. By contrast,
although the growth rate of MDA PCa 180-30 was slowed down after castration (P = 0.008), there was
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a more uniform response to castration in this tumor with a clear relapse occurring in all tumors over
time (Fig 3A). This is in alignment with the fact that MDA PCa 180-30 was derived from a human PCa
that underwent multiple therapies, and therefore there was a selection. These results indicate that the
MDA PCa PDXs are useful models to study CRPC progression.
Although, further analysis of these tumors is beyond the scope of this report, in a technical note, when
we find a statistically significant difference in tumor volume between drug vs vehicle treated mice, we
perform morphological, IHC and molecular analysis of tumors. Briefly, we cut a longitudinal section
in the middle of the harvested tumor and prepare FFPE blocks for morphological and IHC analysis.
Adjacent tissue pieces are cut and flash freeze for molecular studies. Alternatively, fresh tissue can be
used to perform single cell sequencing. One benefit of performing preclinical studies using PDXs in
mice is that certain immunohistochemical and molecular studies can be species specific.
Effect of a specific pan-FGFR inhibitor on two bone-derived PDXs
Bone-forming metastases dominate the clinical picture of men with CRPC (15, 16). Studies by our
group and others have implicated the fibroblast growth factor (FGF) axis in the pathogenesis of PCa
bone progression (5, 17), and we showed that blockade of FGFRs with the receptor tyrosine kinase
inhibitor dovitinib has clinical activity in a subset of men with CRPC and bone metastases (6). More
recent studies implicate the FGF axis in the progression to androgen ablation and other therapies (10,
18). We therefore assessed the antitumor activity of erdafitinib, a novel and selective pan-FGFR
tyrosine kinase inhibitor, preclinically. For these studies we selected two bone-derived PDXs that
recapitulate the bone-forming phenotype observed in human PCa, MDA PCa 118b and MDA PCa 183A (Fig 3B and C). RT-PCR analysis indicated that FGFR1 was high in MDA PCa 118b and about 20fold lower in MDA PCa 183-A. All other receptors were expressed at very low levels (Fig 3B and C).
Accordingly, FGFR1 expression was high in MDA PCa 118b and not detectable in MDA PCa 183-A
at the IHC analysis (Fig 3B and C). Cells derived from these PDXs were injected into the distal ends of
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the femurs of intact male SCID mice according to published protocols (5) and mice subjected to
erdafitinib (12.5 mg/kg body weight BID) or vehicle administration by oral gavage. Potent antitumor
effect of erdafitinib against PCa cells derived from MDA PCa 118b (P < 0.007), but not MDA PCa
183-A, was observed by MR analysis (Fig 3). These results indicate that erdafitinib is active in
controlling the growth of FGFR1-expressing PCa cells in bone and that our PDXs are informative in
the preclinical setting.
The same technical note that was outlined at the end of the previous section applies here, only that in
tumor bearing bones it is challenging to cut each tumor in equally representative pieces. Therefore, we
use a set of bone tumor (one per each mice) for morphological, IHC and molecular studies . Of course,
the flash frozen material will have a significant contribution of mouse (bone) cells. Alternatively, the
femoral shafts of the tumors bearing femur can be flashed to obtain a product enriched for tumor cells.
Copy number alteration in PDXs derived from different areas of the same human PCa
We performed array comparative genomic hybridization (aCGH) to assess copy number changes in
different PDXs derived from the same human PCa donor.
NEC PDXs MDA PCa 144-13 and 144-4 lost cyclin-dependent kinase inhibitor 2A (CDKN2C)
(1p32.3) and PTEN (10q23.31), and had a partial loss of RB (13q14) (Fig S3). However, notable
differences in copy number changes in specific regions were also found (Fig S4, Supplementary
Results).
Common copy number alterations among MDA PCa 146-10, 146-12, and 146-20 were found despite
morphological differences, including loss of PTEN and loss of MAP3K1 via a focal homozygous
deletion in chromosome 5 (Fig S5), which increases sensitivity to MEK inhibition (19). However,
many marked differences in specific regions were identified (Fig S5).
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MDA PCa 153 PDXs are adenocarcinomas that share many gains and losses, including PTEN loss (Fig
4A-C). However, MDA PCa 153-14 has AR amplification and a deletion in the area encompassing the
CDKN2A (Fig 4B), suggesting alternative mechanisms of progression within cells derived from the
same tumor. In this context, it is noticeable that ERG fusion by deletion is very prominent in MDA
PCa 153-7 but not in 153-14, showing further evidence of the intra-tumor heterogeneity typical of PCa
(Fig 4D). Other cases are presented in Supplementary Results (Fig S6 and S7).
These results illustrate the high degree of heterogeneity in PCa which may underlie the diverse
mechanisms of progression to targeted therapies.
Gene expression analysis by next-generation RNA sequencing
We subsequently focused on MDA PCa 144 and MDA PCa 146 pairs to better understand human PCa
heterogeneity at the gene expression level. We found a strong correlation in gene expression between
MDA PCa 144-4 and 144-13 PDXs (r = 0.89 to 0.90) (Fig 4E, upper panels). However, 3351 genes are
differentially regulated between these PDXs (Table S3), and gene set enrichment analysis (GSEA)
identified hallmark MYC, E2F, and G2M checkpoints as the most significantly enriched target gene
sets in MDA PCa 144-13 (Fig 4E, lower panels). This is in alignment with the 47-fold higher
expression of MYC in MDA PCa 144-13 compared with 144-4 (Table S4). New therapeutic
approaches are emerging to target this oncogene (20).
We also found a strong correlation in gene expression between MDA PCa 146-10 and 146-12 (Fig 4F,
upper panels). However, 3022 genes are differentially regulated between these PDXs (Table S5), and
GSEA showed that hallmark androgen response genes and fatty acid metabolism target genes are
among the most significantly enriched in MDA PCa 146-12 compared with 146-10 (Fig 4F, lower
panels and Table S6). This is in alignment with our previous finding that MDA PCa 146-12, but not
146-10, expresses AR (Fig 1D). Recent studies demonstrate that AR is tightly linked with lipogenesis
in PCa and suggest that targeting fatty acid metabolism will inhibit AR signaling (21). Our studies
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emphasize the clinical relevance of MDA PCa PDX models in reflecting the heterogeneity of PCa and
identifying different pathways (e.g., MYC, AR signals) that drive the growth of heterogeneous cell
populations within a single cancer.
Copy number alteration and SPOPL mutational analyses
Results of aCGH analysis of 37 PDXs derived from 28 human tissues identified gains and losses
previously reported for PCa (13) (Fig S8). Table S7 outlines specific rearrangements (TMPRRS2ERG/DSCAM/PRDM15/ETV1), amplifications (AR, MYC), and deletions (PTEN, SPOP, SPOPL,
and P53) identified in these PDXs.
Importantly, by aCGH, we observed that 9 PDXs derived from 7 human PCa donors displayed a focal
deletion in the area encompassing speckle-type POZ protein-like (SPOPL) gene (7/28, 25%) (Fig 5A,
Table S7). Deletions in SPOPL have been previously reported in PCa (22) and comprise about 7% of
the PCas in TCGA dataset (22) (Fig 5B). SPOPL is a MATH-BTB protein that shares an overall 85%
sequence identity with SPOP (a SPOPL paralog). SPOP was recently reported to be mutated in about
8% of PCas and defines a molecular subclass (23). No mutations were found in SPOP in our cohort,
but we found a heterozygous deletion in a region including SPOP (17q21.33) in MDA PCa 101 (Fig
5C). Other focal deletions identified in our PDXs include those spanning tumor suppressors TP53
(17p13.1), CDKN1B (12p13.1), MAP3K1 (5q11.2), and FANCD2 (3p26) (MDA PCa 79; 101; 115C1; 146-10, -12, -20; 160-29; and 183-A). These genomic alterations have been reported in human
PCa (22, 23), which further supports the clinical relevance of our models.

DISCUSSION
The MDA PCa PDX series includes models derived from PCas encompassing the entire clinical
spectrum, including hormone-naïve and CRPC, primary tumors and metastases, typical and AVPC. It
also includes PCa morphological variants (e.g., adenocarcinoma, NEC). As the MDA PCa PDX
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program is constantly accruing samples for PDX development, it captures the evolving molecular
landscape of PCa progressing under novel therapies. To date, we have 154 PDXs derived from 99 PCa
patients, including the non-archived models from the 47 human donor tumors described here that can
be expanded either as cell lines (MDA PCa 2a and 2b) or PDXs. The racial distribution of patient
donors of the established PCa models reflects the patient population treated at our institution (88
Caucasian, 6 African American, and 5 Hispanic).
Previous sequencing studies of multiple metastatic sites at different times provided unique insights into
tumor evolution (24, 25). However, tissue samples obtained at certain time points during therapy are
snapshots of progression. The MDA PCa PDX series provides a biological tool to study the role of
these alterations in the progression of the disease experimentally. Further, current clinical trials in
metastatic CPRC focus on targeting pathways that are altered in this advanced disease state. Clinical
trials are the benchmark for establishing the therapeutic activity of drugs, and the value of biomarkers
of response and/or resistance to drugs should be established in prospective studies. But studies
involving patients and patients’ biological material are limited owing to feasibility, cost, and ethical
constraints. Therefore, PDXs are particularly important for establishing the preclinical antitumor
activity and tolerability of new drugs or drug combinations prior to clinical studies. The use of PDXs is
also important for determining the contribution of the tumor microenvironment (e.g., bone) to PCa
progression and resistance to therapy, the antitumor effect of drugs, the identification of predictors of
treatment response and the emergence of drug-resistant clones (biomarker identification). This
evidence underscores the importance of the availability of PDXs in the preclinical setting for drug
selection, therapy development, selection of markers of treatment response, and identification of
promising combination treatment strategies. Further, advances in therapy development can be achieved
by integrated analysis of clinical and co-clinical studies with PDXs.
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One of the most important subjects of PCa research is the identification of mediators of progression
and resistance to therapy (relapse), which can be accelerated by using preclinical approaches. A deep
understanding of the molecular mechanisms underlying the results of these preclinical studies requires
the ability to introduce genetic alterations into PCa cells. However, as it happens with human PCa
cells, PCa cells derived from PDXs do not establish as cell lines, which is a significant obstacle to
genetically editing these cells. The recent establishment of organoid technology (26, 27) provides a
biological platform for PCa cell propagation in vitro, that can be manipulated (e.g., genetic
manipulation, in vitro selection). This new methodology complements PDXs as preclinical models of
PCa. However, 3D organoid growth conditions do not recapitulate the tumor microenvironment. Thus,
findings using 3D organoids need to be complemented by studies using PDXs to translate those
findings to the clinic (28). One final point that has not been successfully addressed by PDXs is the
study of the immune system in cancer (28).
SPOPL is a component of a cullin-based ubiquitin ligase complex and its clinical significance is
reported for medulloblastoma (29). In TCGA provisional dataset, SPOP mutation was reported in 11%
and SPOPL was deleted in 7% of primary PCa with a tendency to co-occur (Fig 5B). Interestingly, in
the SU2C/PCF dream team dataset (23), this co-occurrence is absent. There is an increase in SPOP
amplification and a reduction in the incidence of both SPOP mutation and SPOPL deletion, but the
combination of these alterations totaled 8% (Fig 5D). The enriched incidence of SPOP mutations in
earlier disease relative to metastatic CRPC has been reported by others (22, 30). Together these results
suggest that there is a selection for mutually exclusive SPOP mutation or SPOPL loss in metastatic
CRPC. Our cohort is enriched for SPOPL deletions, and therefore constitutes a unique resource to
study the role of SPOPL deletion in CRPC.
Finally, we show here that the response of the PDX to castration is different depending on the source
of the PDX (e.g., tumor donor prior therapy) and as expected, PDXs derived from a treatment-naïve
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tumor have a better response to castration than those derived from PCas that progress after therapy.
Further, our models also reflect the bone phenotype typical of PCa bone metastases and predict tumor
response to targeted therapies.
In summary, The MDA PCa PDX collection presented here include adenocarcinoma and NEC PDXs
derived from primary prostate cancers and bone metastases, being prostate and bone the two most
frequent sites of progression. These were obtained from therapy naïve and prostate cancers progressing
on androgen deprivation and chemotherapy. Therefore, constitutes a unique, clinically relevant,
resource for preclinical studies to understand mechanisms of treatment response and resistant to
standard as well as less common therapies (e.g., gefitinib). In this context, of particular relevance is the
availability of PDXs derived from different areas of the same tumor that would enable the
identification of divergent mechanism of progression to therapy in the same tumor due to molecular
heterogeneity. Also, the MDA PCa PDXs cohort presented here is unique in that is enriched for
SPOPL deletions”
Finally, our studies are in line with those of others (31, 32), demonstrating that MDA PCa PDXs
reflect the human donor tumor and are useful for drug testing (33). Furthermore, MDA PCa PDXs
have provided unique insights into the biology of PCa. For example, a study of MDA PCa 118b
implicated the FGF axis in the pathogenesis of PCa bone metastasis (5), which led to the initiation of a
study that demonstrated clinical activity (6). Subsequent studies using our MDA PCa PDXs implicated
the FGF axis in progression to therapy (18). A recent study confirmed our reports of the role of the
FGF axis in the pathogenesis of advanced PCa (10) and reported a new subgroup that utilizes the FGF
axis in progression. MDA PCa 118b fell within this subgroup, further attesting the clinical relevance of
our models. Furthermore, the MDA PCa PDXs contributed to the discovery of distinct classes of
chromosomal rearrangements in PCa cells (34), the identification of new therapeutic approaches for
combination therapy targeting DNA damage response genes (35, 36), the elucidation of new biological
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roles of genes in PCa (37), and the identification of new mechanisms underlying neuroendocrine
differentiation (38). A list of studies that have used the MDA PCa PDXs developed in our program is
outlined in Table S1-Addendum.
Conclusions. The MDA PCa PDX series provides insight into the biological basis that accounts for
PCa heterogeneity and serves as an invaluable resource for discovery, therapy development, and
optimization of personalized therapy targeting PCa-specific drivers of progression. PCa lag behind
other tumor types in the marker-informed classification for treatments. The transition to such
classification can be achieved by linking detailed characterization of human cancers to “driver
mechanisms” in model systems.
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FIGURE LEGENDS
Fig 1. (A) Schematic diagram outlining the strategy for MDA PCa PDX development, expansion,
and storage. PCa tissue samples are implanted subcutaneously into mice. Once the tumor grows,
PDXs are expanded in mice to passage 5. At each passage, representative samples of PDX tissue are
stored in various forms (e.g., fresh-frozen, formalin-fixed and paraffin-embedded) to create a PDX
model repository. The table “Human PCa Donor for PDX Development” indicates the origin of the
samples that developed into the MDA PCa PDXs used in this work. (B) Human donor
adenocarcinomas and corresponding PDXs have the same morphological and
immunohistochemical profile. Representative photomicrographs of HE sections and
immunohistochemical stains for AR. PCa donor tumor of MDA PCa 133 was a bone metastasis and
PCa donor tumor of MDA PCa 173 was a primary PCa. (C) Human donor neuroendocrine
carcinomas and corresponding PDXs have the same morphological and immunohistochemical
profile. Representative photomicrographs of HE sections and immunohistochemical stains for AR,
and markers of neuroendocrine differentiation CGA, SNP, and CD56. PCa donor tumor of MDA PCa
150 was a bone metastasis, and PCa donor tumor of MDA PCa 155 was a primary PCa. (D) PDXs
derived from a mixed adenocarcinoma/neuroendocrine human PCa. Representative
photomicrographs showing the adenocarcinoma and neuroendocrine components of human PCa
reflected in different PDXs. PCa donor tumor of MDA PCa 146 was a primary PCa. (E)
Morphological distribution (adenocarcinoma and neuroendocrine carcinoma) of MDA PCa PDXs
reported in this work. (F) AR, ERG, and PTEN status of MDA PCa PDXs reported in this work. HE,
hematoxylin and eosin; AR, androgen receptor; CGA, chromogranin; SNP, synaptophysin.
Fig 2. Table outlines the status of ERG, PTEN, and AR in 11 pairs of human PCa (Tumor) and
corresponding PDX (PDX). Representative photomicrographs show examples of ERG staining in the
human prostate donor tumor and PDX in two different pairs. Note that in those cases in which multiple
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PDXs were generated from different areas of the same tumor (e.g., MDA PCa 144-4, -13, etc; and
MDA PCa 146-10; -12, etc) we did not include a suffix that uniquely identifies each individual PDX
because this is only an illustration of the different phenotypes found. Table S2 lists the specific
phenotype identified in each of these unique PDXs.
Fig 3. (A) Effect of mouse castration on the growth of two MDA PCa PDXs. MDA PCa 183-A.
Intact mice. Tumor volume monitoring detected a significant increase over time (n = 9, slope = 18.0;
P < 0.0001, linear mixed models). Castrated mice. Tumor volume monitoring after mouse castration
did not detect any significant change over time (n = 7, slope = -0.4; P = 0.85). There was a statistically
significant difference between the slopes of tumor volume between the intact and castrated mice (P <
0.0001). Tumor volume before and after castration. A piecewise linear mixed model, with
castration day as the cutoff, suggests that there was a statistically significant increase in tumor volume
before castration (n = 4, slope = 26.8, P < 0.0001), and there was a statistically significant decrease in
tumor volume after castration (n = 6, slope = -18.0, P < 0.0001). MDA PCa 180-30. Intact mice.
Tumor volume monitoring detected a significant increase over time (n = 7, slope = 41.7; P < 0.0001,
linear mixed models). Castrated mice. Tumor volume monitoring after mouse castration detected a
significant increase over time, although the rate of increase (i.e., slope) was smaller than in intact mice
(n = 14, slope = 26.4; P < 0.0001). There was a statistically significant difference between the two
slopes (P = 0.008). Tumor volume before and after castration. A piecewise linear mixed model,
with castration day as the cutoff, suggests that there was a statistically significant increase in tumor
volume before castration (n = 14, slope = 36.3, P < 0.0001). Also, there was a statistically significant
increase (although at a lower rate) in tumor volume after castration (n = 14, slope = 30.9, P < 0.0001).
Tumor volumes based on caliper measurements were calculated by the modified ellipsoidal formula:
1/2(length × width2). (B) Effect of erdafitinib in MDA PCa 118b PDXs growing in the bone of
immunodeficient mice. Bone scan (front view) and contrast enhanced CT scan show the lesion
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involving the left ilium (arrow) that was the source of MDA PCa 118b PDX. X-ray of a mouse pelvis
and rear limbs 5 weeks after intrafemoral implantation of MDA PCa 118b–derived cells. mRNA
expression by RT-PCR of FGFR1, FGFR2, FGFR3, FGFR4 in mouse femurs using human-specific
primers. FGFR1 immunohistochemistry (IHC) of an MDA PCa 118b–bearing femur shows high
FGFR1 expression. An example of MR images of MDA PCa 118b tumor–bearing femur in erdafitinib
and vehicle-treated mice. The graph shows the quantification of tumor volume. (C) Effect of
erdafitinib in MDA PCa 183-A PDXs growing in the bone of immunodeficient mice. Bone scan
(rear view) and CT scan show the bone lesion involving the sacrum that was the source of the MDA
PCa 183 cells (arrow). X-ray of a mouse pelvis and rear limbs 9 weeks after intrafemoral implantation
of MDA PCa 183-A–derived cells. mRNA expression by RT-PCR of FGFR1, FGFR2, FGFR3,
FGFR4 in mouse femurs using human-specific primers. FGFR1 IHC of MDA PCa 183-A–bearing
femur shows no FGFR1 expression. An example of MR images of MDA PCa 183-A–bearing femur in
erdafitinib and vehicle-treated mice. The graph shows the quantification of tumor volume. T, tumor; B,
bone.
Fig 4. A-C, whole-genome analysis of MDA PCa 153 PDXs. (A) Comparison of copy number
changes at whole genome level in MDA PCa 153-7 (red) and MDA PCa 153-14 (blue) identified many
common losses and gains, as well as notable differences in copy number between the two PDXs
(boxed areas). (B) Both MDA PCa 153-7 (red) and MDA PCa 153-14 (blue) have a PTEN deletion.
However, MDA PCa 153-14 (but not -7) has AR amplification and a deletion in the area encompassing
the cyclin-dependent kinase inhibitor 2A (CDKN2A). (C) Notable differences in copy number
between the two PDXs can be appreciated at higher resolution. (D) Chromosome view and gene view
of ERG fusion by deletion, which is very prominent in MDA PCa 153-7 but not in 153-14. E-F, RNA
sequencing analysis of MDA PCa 144 and MDA PCa 146 pairs. (E) Heat maps illustrate correlation
and differential expression of genes between MDA PCa 144 and MDA PCa 146 PDX pairs. For the
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differential expression analysis, significant genes are defined using FDR 0.01 and fold change of 2. (F)
Four hallmark gene sets among the most significantly enriched in MDA PCa 144-13 vs MDA PCa
144-4 (left panels) and MDA PCa 146-10 vs MDA PCa 146-12 (right panels).
Fig 5. (A) Recurrent focal deletion in areas that include the SPOPL gene in MDA PCa PDXs
derived from 7 human donors. High resolution aCGH analysis identified focal deletion in the area
encompassing SPOPL gene in 9 PDXs derived from 7 human PCa donors. B-D, SPOP and SPOPL
status in PCa. (B) SPOP and SPOPL status in TCGA provisional dataset. (C) Heterozygous deletion
in a region including SPOP (17q21.33) in the MDA PCa 101 PDX identified by aCGH. (D) SPOP and
SPOPL status in SU2C/PCF dream team dataset. Data from TCGA and SU2C/PCF dream team were
obtained from cBioPortal (39, 40).

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

30
TABLES
Table 1. Morphological and IHC findings in human donor tumors and PDXs. IHC for neuroendocrine markers was performed only
on AR– cases with neuroendocrine morphology
Human PCa of Origin
Specimen Tumor
number
Site

2

117

Bone

Diagnosis

Adenocarcinoma

Gleason
Grades

N/A

Clinical
State

CRPC

Prostate Adenocarcinoma

4+5

CRPC

118

Bone

Adenocarcinoma
(SNP-, CGA-)

N/A

CRPC

133

Bone

Adenocarcinoma

N/A

CRPC

PDX or Cell Line Derived Xenograft
Treatment history at the
PDX / Cell line
time of tissue
name
acquisition
Bilateral orchiectomy;
suramine+doxorubicin;
vertebral resection

MDA PCa 2aT#
MDA PCa 2bT#

Leuprolide+bicalutamide;
autologous dendritic
MDA PCa 117vaccine; gefitinib;
9
docetaxel
Leuprolide+bicalutamide;
paclitaxel+carboplatin+
MDA PCaDES; skull/shoulder
118b
radiation
Local
radiation+leuprolide
+bicalutamide
+ketoconazole;
docetaxel+estramustine;
thalidomide+paclitaxel
MDA PCa 133+estramustine;
4
docetaxel+imatinib;
ifosfamide+mitoxantrane
+gemcitabine; etoposide+
mitoxantrane; gefitinib+
mitoxantrane; vertebral
resection

Diagnosis@
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma

Adenocarcinoma (AR-,
SNP-, CGA-, CD56+)

Adenocarcinoma

MDA PCa 144- Neuroendocrine carcinoma
4
(AR-, SNP+, CGA +)

144

Mixed
adenocarcinoma
Prostate,
(AR+) and
Bladder, neuroendocrine
Rectum carcinoma (AR-,
SNP+, CGA+,
CD56 +)

MDA PCa 144- Neuroendocrine carcinoma
6
(AR-, SNP+, CGA +)
N/A

CRPC

Local radiation+hormonal
Neuroendocrine carcinoma
therapy; leuprolide;
MDA PCa 144(AR-, SNP+, CGA+,
docetaxel+carboplatin;
11
CD56+)
etoposide+cisplatin
Neuroendocrine carcinoma
MDA PCa 144(AR-, SNP+, CGA+,
13
CD56+)
MDA PCa 14420

Neuroendocrine carcinoma
(AR-, SNP+, CGA+,
CD56+)
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MDA PCa 146- Neuroendocrine carcinoma
10
(AR-, SNP+, CGA+)

146

149

Mixed
adenocarcinoma
(AR+) and
Bladder neuroendocrine
carcinoma
(SNP+, CGA+,
CD56+)

5+4

Bladder Adenocarcinoma

4+5

CRPC

CRPC

MDA PCa 14612

Adenocarcinoma (AR+,
SNP-, CGA-)

MDA PCa 14620

Mixed adenocarcinoma
and neuroendocrine
carcinoma (AR-, SNP+,
CGA+)

Brachytherapy+
Leuprolide+
MDA PCa 146- Neuroendocrine carcinoma
bicalutamide; docetaxel
17
(AR-, SNP+, CGA+)

RPx+leuprolide+local
MDA PCa 149radiation; bicalutamide;
1
docetaxel

Adenocarcinoma

Neuroendocrine carcinoma
MDA PCa 150(AR-, SNP weak, CGA+,
1
CD56+)

150

Bone

Neuroendocrine
carcinoma (AR-,
SNP weak,
CGA+, CD56+)

Neuroendocrine carcinoma
MDA PCa 150(AR-, SNP weak, CGA+,
3
CD56+)
N/A

CRPC

Neuroendocrine carcinoma
RPx+leuprolide+CCI-779 MDA PCa 150- (AR-, SNP weak, CGA+,
5
CD56+)
Neuroendocrine carcinoma
MDA PCa 150(AR-, SNP weak, CGA+,
7
CD56+)
Neuroendocrine carcinoma
MDA PCa 150(AR-, SNP weak, CGA+,
10
CD56+)

152

153

Brain

Adenocarcinoma
(ductal)

Thyroid
Adenocarcinoma
Gland

N/A

N/A

CRPC

CRPC

RPx+leuprolide+local
radiation

MDA PCa 1521
MDA PCa 1525

Leuprolide+
MDA PCa 153bicalutamide; goserelin;
7
DES; Immunotherapy
(NY-ESO-1 plasmid MDA PCa 15314
DNA vaccine)

Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma

Neuroendocrine carcinoma
(AR-, SNP+, CGA+,
CD56+)
Neuroendocrine carcinoma
MDA PCa 155(AR-, SNP+, CGA+,
9
Leuprolide+bicalutamide
CD56+)
+docetacel+carboplatin;
Neuroendocrine carcinoma
MDA PCa 155cisplatin+etoposide
(AR-, SNP+, CGA+,
12
CD56+)
MDA PCa 1552

155

Neuroendocrine
Prostate, carcinoma (AR-,
Bladder
SNP weak,
CGA+, CD56+)

N/A

CRPC

MDA PCa 15516

Neuroendocrine carcinoma
(AR-, SNP+, CGA+,
CD56+)
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166

Bladder Adenocarcinoma

5+4

CRPC

170

Prostate Adenocarcinoma

5+4

CRPC

173

Prostate Adenocarcinoma

3+4

Naïve

175

Testis

Adenocarcinoma

Poorly
differentiated
carcinoma
(SNP-, CGA-)

177

Prostate

178

Prostate Adenocarcinoma

180

181

182

183
188

N/A

Prostate,
Adenocarcinoma
Bladder

Mixed
adenocarcinoma
(NE-) and
Bladder neuroendocrine
carcinoma
(SNP+, CGA+,
CD56+)

Prostate Adenocarcinoma

Bone

N/A

*

CRPC

CRPC

Ketoconazol+leuprolide+
MDA PCa 166bicalutamide+carboplatin
1
+docetaxel
Leuprolide+bicalutamide MDA PCa 1701
+docetaxel;
cyclophosphamide+
MDA PCa 170vincristine
4
MDA PCa 173Therapy-naïve
2
MDA PCa 1752
Leuprolide+bicalutamide;
ketoconazole; paclitaxel MDA PCa 175+DES;
6
samarium+doxorubicin) MDA PCa 17510

Hormone
MDA PCa 178Leuprolide+bicalutamide
Responsive
11

5+4

MDA PCa 18011
MDA PCa 18014
Leuprolide+bicalutamide MDA PCa 180+docetaxel+carboplatin
18
MDA PCa 18021
MDA PCa 18030

N/A

5+4

CRPC

CRPC

Adenocarcinoma

N/A

Naïve

Bladder Adenocarcinoma

5+4

CRPC

Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma

Poorly differentiated
carcinoma with
MDA PCa 177- morphology suggestive of
Goserelin+bicalutamide
B
neuroendocrine features
(AR-, SNP-, CGA-,
CD56+)

4+5

CRPC

Adenocarcinoma

Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma

Brachytherapy; goserelin;
Neuroendocrine carcinoma
paclitaxel+carboplatin;
MDA PCa 181 (AR-, SNP weak, CGA-,
etoposide+cisplatin;
CD56+)
paclitaxel+ doxorubicin)

Local radiation;
MDA PCa 182leuprolide+bicalutamide
7
+DES; docetaxel,
carboplatin, etoposide+ MDA PCa 18211
cisplatin.)
MDA PCa 183Therapy-Naïve
A
RPx; leuprolide+
bicalutamide+docetaxel; MDA PCa 188
carboplatin+paclitaxel

Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
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*Diagnosis per report, no material was available to review; #Indicates cell line–derived xenograft (for simplicity, when we say PDXs
this will be inclusive of MDA PCa 2a-T and 2b-T); @Morphology of PDX was the same at early (passage 1-3) and late passages
(passage 5-6); N/A, not applicable; IHC, immunohistochemistry; CRPC, castration resistant prostate cancer; AR, androgen receptor;
SNP, synaptophysin; CGA, chromogranin; DES, diethylstilbestrol; RPx: radical prostatectomy.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on June 23, 2020; DOI: 10.1158/1078-0432.CCR-20-0479
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

The MD Anderson prostate cancer patient-derived xenograft
series (MDA PCa PDX) captures the molecular landscape of
prostate cancer and facilitates marker-driven therapy
development
Nallasivam Palanisamy, Jun Yang, Peter D. A. Shepherd, et al.
Clin Cancer Res Published OnlineFirst June 23, 2020.

Updated version
Supplementary
Material
Author
Manuscript

E-mail alerts
Reprints and
Subscriptions
Permissions

Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-20-0479
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2020/06/20/1078-0432.CCR-20-0479.DC1
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
edited.

Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Department at pubs@aacr.org.
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/early/2020/06/23/1078-0432.CCR-20-0479.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
Rightslink site.

Downloaded from clincancerres.aacrjournals.org on July 14, 2020. © 2020 American Association for Cancer
Research.

